Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.

< BACK TO ARCHIVE


2022 Mar 03


Ann Rheum Dis


http://www.ncbi.nlm.nih.gov/pubmed/35241426?dopt=Abstract

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.

Authors

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.
Mease PJ, Deodhar AA, van der Heijde D, Behrens F, Kivitz AJ, Neal J, Kim J, Singhal S, Nowak M, Banerjee S
Ann Rheum Dis. 2022 Mar 03.
PMID: 35241426.

Abstract

To evaluate the efficacy and safety of an oral selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib, in patients with active psoriatic arthritis (PsA).
Read This Paper